ArticleHepatology international2024

Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy.

Kuan-Chang Lai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.